The Risk of recurrence in prostate cancer
by: Fritz Frei
Prostate cancer disease
Prostate cancer - the most common form of cancer in men is Prostate cancer, the second leading cause of cancer death. The Main risk factors include age (incidence increases in men over the age of 65 years). It is more prevalent in the western world and about 10% of cases can be linked to family history. The recurrance Rate of the prostate cancer is high.
Mostly, the Prostate cancer is a continuum; progressing through localized, locally advanced, advanced and hormone-refractory stages In general it is a slow growing cancer. He is primarily under hormonal control i.e. testosterone. The choice of treatments which include watchful waiting, surgery (prostatectomy), radiotherapy, hormonal therapy and chemotherapy are dependent on the stage of disease.
1. Most important, that If detected early, using PSA determination, DRE examination and biopsies, and treated appropriately, survival rates are excellent.
2. The most critical focus for the treatment of prostate cancer is to treat those cancers where it is necessary.
3. The Decisions about the best management of prostate cancer can be very complex and depend upon the:
- Pathology of the cancer (unlike other cancers, prostate cancer often progresses very slowly)
- The impact that treatment can have on quality of life, including sexual activity
- Stage of the disease (non-metastatic (localized or locally advanced), metastatic or hormone refractory)
- Age and general health of the patients at diagnosis
- Patient’s preference for treatment
- PSA at diagnosis
4. The treatment options for prostate cancer are:
- Deferred treatment often called ‘watchful waiting’ or 'active surveillance'
- Surgery – Radical Prostatectomy
- Radiotherapy – External Beam and/or Brachytherapy
-Hormonal (endocrine) therapy – Androgen Ablation e.g. anti-androgens, medical castration (LHRHa) or surgical castration
- Palliative Therapy e.g. chemotherapy
- Investigational Therapies
Prostate Cancer Recurrence Rates ***
Prostate cancer is now detected at earlier stages due to heightened awareness and improved screening techniques. Despite definitive therapy, cancer cells may remain and can go undetected for years until they develop into metastatic disease. The risk of recurrence is high, suggesting there is a need to improve treatment approaches. Therefore, it is important to predict pathological stage and risk of disease recurrence early, so that appropriate treatment and/or monitoring can be initiated. The result's of all new treatments will bring us in the future the chance of a lower prostate recurrance.
**You can inform you about the recurrence Rates on:
This gives you an overview with a study case – and the results.
Latest Cancer News:
Double mastectomy doesn't boost cancer survival rates: study
Women fighting cancer in one breast don't benefit from having both breasts removed, according to new research out Tuesday, that found long-term survival was equivalent after targeted surgery plus radiation. Hollywood star Angelina Jolie famously announced last year she had a double mastectomy to reduce her risk of one day developing breast cancer, because she has a genetic mutation that ... Double Mastectomy Rise Doesn?t Boost Cancer Survival Rate
The number of women who have both breasts removed following a cancer diagnosis has risen to more than 1 in 10, even as a new study shows the surgery doesn't improve survival over less drastic treatment. About 12 percent of women opted for a double mastectomy in 2011, up from 2 percent in 1998, according to a study released yesterday by the Journal of the American Medical Association. The surgery ... Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT, Receives CE Mark
RUTHERFORD, N.J. -- -- Cancer Genetics, Inc. ("CGI" or "The Company"), an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test ... Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE
RUTHERFORD, N.J. -- -- Cancer Genetics, Inc. ("CGI" or "The Company"), an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test ... Gabriella Miller?s cancer research foundation awards $100,000 grant
The foundation started by the pediatric cancer awareness advocate awards a $100,000 research grant. Exelixis Drug Fails Pivotal Prostate Cancer Study
As a result of the negative prostate cancer study, Exelixis intends to downsize by firing 70% of its workforce. Click to view a price quote on EXEL . Click to research the Drugs industry. Rosetta Genomics and Moffitt Cancer Center Enter Into Strategic Alliance to Develop microRNA-Based Cancer Diagnostics
Rosetta Genomics Ltd. announces that the company has entered into a strategic alliance with Moffitt Cancer Center to discover, develop and commercialize a variety of microRNA-based cancer diagnostics. Teen Diagnosed With Cancer Looks for Cure
Lauren Bendesky was diagnosed with the disease at 14. Skin cancer and survival rates rise
Skin cancer cases have increased two-and-a-half fold over the past 30 years but survival rates have also risen, according to researchers in Glasgow. The Cancer Center At The Children's Hospital Of Philadelphia Kicks Off September's Childhood Cancer Awareness Month
PHILADELPHIA, Sept. 2, 2014 /PRNewswire/ -- The Cancer Center at The Children's Hospital of Philadelphia kicks off September's Childhood Cancer Awareness Month in partnership with childhood cancer patients and survivors, their families and the larger community. This year focuses on the resiliency of kids being treated for cancer. Despite facing the greatest challenge of their lives, children and ... Teen Diagnosed With Cancer Looks for Cure as Researcher - ABC News